KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Non Operating Income (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Non Operating Income for 17 consecutive years, with $51.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 116.72% to $51.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$674.0 million, a 24.52% increase, with the full-year FY2025 number at -$674.0 million, up 24.52% from a year prior.
  • Non Operating Income was $51.0 million for Q4 2025 at Bristol Myers Squibb, down from $108.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $702.0 million in Q1 2021 to a low of -$649.0 million in Q1 2022.
  • A 5-year average of -$13.2 million and a median of $26.5 million in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: tumbled 14300.0% in 2022, then surged 163.64% in 2023.
  • Bristol Myers Squibb's Non Operating Income stood at -$393.0 million in 2021, then soared by 155.22% to $217.0 million in 2022, then skyrocketed by 70.97% to $371.0 million in 2023, then plummeted by 182.21% to -$305.0 million in 2024, then skyrocketed by 116.72% to $51.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Non Operating Income are $51.0 million (Q4 2025), $108.0 million (Q3 2025), and -$494.0 million (Q2 2025).